1. Home
  2. EARN vs CRVS Comparison

EARN vs CRVS Comparison

Compare EARN & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EARN
  • CRVS
  • Stock Information
  • Founded
  • EARN 2012
  • CRVS 2014
  • Country
  • EARN United States
  • CRVS United States
  • Employees
  • EARN N/A
  • CRVS N/A
  • Industry
  • EARN Real Estate Investment Trusts
  • CRVS Biotechnology: Pharmaceutical Preparations
  • Sector
  • EARN Real Estate
  • CRVS Health Care
  • Exchange
  • EARN Nasdaq
  • CRVS Nasdaq
  • Market Cap
  • EARN 189.7M
  • CRVS 459.0M
  • IPO Year
  • EARN 2013
  • CRVS 2016
  • Fundamental
  • Price
  • EARN $5.36
  • CRVS $7.61
  • Analyst Decision
  • EARN Buy
  • CRVS Strong Buy
  • Analyst Count
  • EARN 2
  • CRVS 4
  • Target Price
  • EARN $5.88
  • CRVS $13.75
  • AVG Volume (30 Days)
  • EARN 361.1K
  • CRVS 1.1M
  • Earning Date
  • EARN 11-11-2025
  • CRVS 11-11-2025
  • Dividend Yield
  • EARN 17.94%
  • CRVS N/A
  • EPS Growth
  • EARN N/A
  • CRVS N/A
  • EPS
  • EARN N/A
  • CRVS N/A
  • Revenue
  • EARN $35,893,000.00
  • CRVS N/A
  • Revenue This Year
  • EARN N/A
  • CRVS N/A
  • Revenue Next Year
  • EARN $15.93
  • CRVS N/A
  • P/E Ratio
  • EARN N/A
  • CRVS N/A
  • Revenue Growth
  • EARN 43.30
  • CRVS N/A
  • 52 Week Low
  • EARN $4.33
  • CRVS $2.54
  • 52 Week High
  • EARN $6.99
  • CRVS $10.00
  • Technical
  • Relative Strength Index (RSI)
  • EARN 52.39
  • CRVS 61.71
  • Support Level
  • EARN $5.10
  • CRVS $6.81
  • Resistance Level
  • EARN $5.39
  • CRVS $7.96
  • Average True Range (ATR)
  • EARN 0.08
  • CRVS 0.50
  • MACD
  • EARN 0.04
  • CRVS -0.01
  • Stochastic Oscillator
  • EARN 94.81
  • CRVS 81.67

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: